Form 4: BioCryst CLO Executes Pre-Planned Stock Sale

Chief Legal Officer Alane P. Barnes exercised options and sold 62,500 shares of BioCryst Pharmaceuticals common stock.

Summary

• Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, exercised stock options for 62,500 shares at a strike price of $5.04.
• Following the exercise, the reporting person sold the same 62,500 shares at a market price of $9.54.
• The transactions were executed automatically under a Rule 10b5-1 trading plan adopted on August 13, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 400,703 shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and non-discretionary, reflecting standard executive financial management rather than a reaction to company performance.

Positives

• The transaction was non-discretionary, conducted under a pre-established Rule 10b5-1 trading plan, indicating the sale was not based on immediate non-public information.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Industry Context

StockSavvy.ai notes that executive stock sales conducted via 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed via a 10b5-1 plan.

Next Steps

• None mentioned.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Insider Trading, Form 4, Stock Option Exercise, Rule 10b5-1